Table 1:
Characteristics of the RA clinic population at baseline
| Cross-sectional sample N = 595 |
Longitudinal cohort N = 341 |
|
|---|---|---|
| Age in years, Mean ± SD | 56.5 (15.3) | 55.8 (15.4) |
| Female, n (%) | 493 (83) | 282 (83) |
| BMI, mean ± SD | 26.7 (6.4) | 26.2 (5.9) |
| Race/Ethnicity, n (%) | ||
| White | 297 (50) | 163 (48) |
| African American | 38 (6) | 19 (6) |
| Hispanic | 27 (5) | 14 (4) |
| Asian | 115 (19) | 73 (21) |
| Other | 118 (20) | 72 (21) |
| Preferred language, n (%) | ||
| English | 512 (86) | 288 (85) |
| Spanish | 43 (8) | 28 (8) |
| Chinese | 40 (6) | 25 (7) |
| Insurance type, n (%) | ||
| Private | 236 (40) | 142 (42) |
| Medicare | 281 (47) | 155 (45) |
| Medicaid | 78 (13) | 44 (13) |
| Smoking, n (%) | 137 (23) | 79 (23) |
| Total Charlson score, median (IQR) | 1 (1-2) | 1 (1-2) |
| Medication, n (%) | ||
| DMARD & Biologic Naïve | 26 (5) | 11 (3) |
| DMARD only | 311 (52) | 181 (53) |
| Biologic with or without DMARD | 258 (43) | 149 (44) |
| Clinical Parameters | ||
| RA disease activity, n (%) | ||
| CDAI remission | 85 (14) | 49 (14) |
| CDAI low | 207 (35) | 111 (33) |
| CDAI moderate | 168 (28) | 104 (30) |
| CDAI high | 135 (23) | 77 (23) |
| Physician GA VAS, median (IQR) | 23 (10-44) | 24 (10-44) |
| Patient GA VAS, median (IQR) | 40 (15-64) | 35 (15-62) |
| PF10a, mean ± SD | 40.1 (10.7) | 40.8 (10.4) |
| Pain VAS, median (IQR) | 40 (15-68) | 33 (12-65) |
| Tender 28-Joint Count, median (IQR) | 2 (0-6) | 2 (0-6) |
| Swollen 28-Joint Count, median (IQR) | 2 (0-5) | 2 (0-6) |
| CRP mg/dl, median (IQR) | 4 (2-9.2) | 4 (2-8.6) |
| ESR mm/hr, median (IQR) | 19 (9-36) | 20 (10-35) |
N: Number; SD: Standard deviation; BMI: Body mass index; IQR: interquartile range; DAMRD: disease modifying antirheumatic drug; CDAI: clinical disease activity index; GA: Global assessment; VAS: Visual analogue score; PF10a: PROMIS Physical Function Short Form 10a; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate.